Phaseline

Targets › CXCR4

CXCR4 (C-X-C chemokine receptor type 4): drug programs, companies and trials

16 programs from 15 companies in 20 trials: 8 Phase 2, 8 Phase 1, 3 Phase 3, 1 Phase 4; Oncology, Hematology, Infectious disease; next expected readout Dec 2026.

Receptor for the C-X-C chemokine CXCL12/SDF-1 that transduces a signal by increasing intracellular calcium ion levels and enhancing MAPK1/MAPK3 activation. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of downstream effectors, such as adenylate cyclase. (UniProt, P61073)

Open in Phaseline: the race on CXCR4, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Guangzhou Gloria BiosciencesMotixafortide (BL-8040)
C-X-C chemokine receptor type 4 antagonist
CXCR4Phase 3Multiple Myeloma; Pancreatic Cancer; Acute Myeloid Leukemia; Sickle Cell DiseaseMay 2027
X4 PharmaceuticalsMavorixafor
C-X-C chemokine receptor type 4 antagonist
CXCR4Phase 3NeutropeniaSep 2027
BioLineRxMotixafortide (BL-8040)
C-X-C chemokine receptor type 4 antagonist
CXCR4Phase 3Multiple MyelomaSep 2029
Koo Foundation Sun Yat-Sen Cancer CenterGa-68-CXCR4
CXCR4-targeting radiopharmaceutical for PET/CT imaging
CXCR4Phase 2Indolent B-Cell Non-Hodgkin LymphomaApr 2027
Memorial Sloan Kettering Cancer CenterPlerixafor
C-X-C chemokine receptor type 4 partial agonist
CXCR4Phase 2Diffuse Large B-cell Lymphoma (DLBCL)Oct 2027
Thomas Jefferson UniversityPlerixafor
C-X-C chemokine receptor type 4 partial agonist
CXCR4Phase 2Multiple MyelomaDec 2027
Nantes University Hospital[68Ga]Ga-PentixaFor
CXCR4-targeting radiopharmaceutical for PET imaging
CXCR4Phase 2Multiple MyelomaDec 2029
National Institute of Allergy and Infectious Diseases (NIAID)Plerixafor
C-X-C chemokine receptor type 4 partial agonist
CXCR4Phase 2Idiopathic CD4-PositiveOct 2030
IRCCS San RaffaelePlerixafor
C-X-C chemokine receptor type 4 partial agonist
CXCR4Phase 2Chronic Granulomatous Disease X-linked (X-CGD)–
The First Affiliated Hospital of Soochow UniversityCXCR4-enabled CCR9 chimeric antigen receptor T-cell injection
CAR-T cells engineered to express chimeric antigen receptors targeting CXCR4 and CCR9
CXCR4, CCR9Phase 1Relapsed/Refractory T-lymphoblastic Leukemia/LymphomaDec 2026
Peking Union Medical College Hospital68Ga-Pentixafor
CXCR4-targeted PET/CT imaging agent
CXCR4Phase 1Cushing s SyndromeFeb 2027
M.D. Anderson Cancer CenterPlerixafor
C-X-C chemokine receptor type 4 partial agonist
CXCR4Phase 1RUNX1 Familial Platelet DisorderJun 2027
City of Hope Medical CenterPlerixafor
C-X-C chemokine receptor type 4 partial agonist
CXCR4Phase 1Sickle Cell DiseaseJul 2027
National Cancer Institute (NCI)Plerixafor
C-X-C chemokine receptor type 4 partial agonist
CXCR4Phase 1HIVJul 2027
Nantes University Hospital[177Lu]Lu-PentixaTher
CXCR4-targeting radioligand therapy (177Lu-based radiopharmaceutical)
CXCR4Phase 1Acute LeukemiaOct 2027
St. Jude Children's Research HospitalPlerixafor
C-X-C chemokine receptor type 4 partial agonist
CXCR4Phase 1Bone Marrow Failure SyndromeDec 2028

Conditions

Multiple Myeloma (5) Sickle Cell Disease (2) Indolent B-Cell Non-Hodgkin Lymphoma (1) Pancreatic Cancer (1) Acute Myeloid Leukemia (1) Idiopathic CD4-Positive (1) Diffuse Large B-cell Lymphoma (DLBCL) (1) Acute Leukemia (1) Neutropenia (1) Chronic Granulomatous Disease X-linked (X-CGD) (1) RUNX1 Familial Platelet Disorder (1) HIV (1)

Modalities

small molecule (10), mixed (4), protein or peptide (1), other (1)

Companies

Nantes University Hospital (2) Koo Foundation Sun Yat-Sen Cancer Center (1) Guangzhou Gloria Biosciences (1) BioLineRx (1) National Institute of Allergy and Infectious Diseases (NIAID) (1) Memorial Sloan Kettering Cancer Center (1) X4 Pharmaceuticals (1) IRCCS San Raffaele (1) M.D. Anderson Cancer Center (1) National Cancer Institute (NCI) (1) City of Hope Medical Center (1) Thomas Jefferson University (1) The First Affiliated Hospital of Soochow University (1) St. Jude Children's Research Hospital (1) Peking Union Medical College Hospital (1)

Related targets

CCR9 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.